Year None202320222021202020192018201720162015201420132012 Mar 9 2023 Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Feb 23 2023 Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 Feb 21 2023 Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings Feb 7 2023 Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 Feb 6 2023 Clearside Biomedical Announces Leadership Team Update Feb 2 2023 Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
Mar 9 2023 Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Feb 23 2023 Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
Feb 21 2023 Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
Feb 7 2023 Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
Feb 2 2023 Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
